ABS 118
Alternative Names: ABS-118Latest Information Update: 17 Oct 2024
Price :
$50 *
At a glance
- Originator Amberstone Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 17 Oct 2024 Early research in Solid tumours in USA (Parenteral), prior to October 2024 (Amberstone Biosciences pipeline, October 2024)